Kevin Houston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kevin Houston has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- David A. Johnsonv
Division of Gastroenterology, Macon and Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23501, USA
10 shared publications - Byung Soo Yoo
Department of Gastroenterology, Carolinas Medical Center, Charlotte, NC 28203, USA
7 shared publications - Steven M. D’souza
Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA 23507, USA
5 shared publications - Ana Rosa Vilela Sangay
Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA, USA
4 shared publications - Michael Saadeh
Internal Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, United States
4 shared publications - Alejandra Vargas
Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA, USA
3 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 28 (1)
Liver Disease in Older Adults: Diagnosis, Management, and Transplantations
Purpose of Review: To summarize age-specific considerations in the diagnosis and management of liver disease in adults aged 65 years and older, with emphasis on cirrhosis, liver transplantation, frailty, and cognitive impairment. Recent Findings: Age alters the performance and tolerability of commonly used diagnostic and therapeutic strategies. Age-adjusted interpretation of serum fibrosis tests, sequential use of elastography, careful titration of cirrhosis therapies, and routine frailty assessment can reduce avoidable harm. Transplant outcomes in carefully selected older recipients remain acceptable, and chronological age alone should not determine candidacy. Summary: The care of the older adults with liver disease should integrate disease severity with physiologic reserve, comorbidity, function, medication safety, and cognition. A structured evaluation is particularly important when hepatic encephalopathy overlaps with delirium or dementia.
- 18 November 2026
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 28 (1)
Open AccessLiver Disease in Older Adults: Diagnosis, Management, and Transplantations
Purpose of Review: To summarize age-specific considerations in the diagnosis and management of liver disease in adults aged 65 years and older, with emphasis on cirrhosis, liver transplantation, frailty, and cognitive impairment. Recent Findings: Age alters the performance and tolerability of commonly used diagnostic and therapeutic strategies. Age-adjusted interpretation of serum fibrosis tests, sequential use of elastography, careful titration of cirrhosis therapies, and routine frailty assessment can reduce avoidable harm. Transplant outcomes in carefully selected older recipients remain acceptable, and chronological age alone should not determine candidacy. Summary: The care of the older adults with liver disease should integrate disease severity with physiologic reserve, comorbidity, function, medication safety, and cognition. A structured evaluation is particularly important when hepatic encephalopathy overlaps with delirium or dementia.
- Open Access
- 12 November 2026
- Published by MDPI AG in Microplastics
- Vol. 5 (4) , 229
Micro- and Nanoplastics and Liver Disease: Mechanistic Insights, Experimental Evidence, and Pathways to Hepatic Inflammation, Fibrosis, and Carcinogenesis
Micro–nanoplastics (MNPs) have emerged as a critical environmental pollutant with significant potential implications for the development of liver disease. These MNPs can accumulate in the liver, initiating a series of detrimental biological responses. One of the main mechanisms is the initiation of oxidative stress, which is marked by overproduction of reactive oxygen species harming cellular structures. This oxidative damage is closely linked to hepatic inflammation, where immune responses are triggered, exacerbating tissue injury and disrupting normal liver function. As a result, hepatic metabolism, detoxification, and immune regulation become compromised due to persistent MNPs exposure. Although in vitro and vivo models effectively show direct cellular toxicity, oxidative stress, and metabolic disruption, direct evidence from human studies is mostly confined to tissue detection and cross-sectional correlations. As a result, advanced pathological outcomes like the progression of hepatic fibrosis and the development of cancer are considered mechanistic hypotheses grounded in biological plausibility rather than confirmed human causation.
- 12 November 2026
- Published by MDPI AG in Microplastics
- Vol. 5 (4) , 229
Open AccessMicro- and Nanoplastics and Liver Disease: Mechanistic Insights, Experimental Evidence, and Pathways to Hepatic Inflammation, Fibrosis, and Carcinogenesis
Micro–nanoplastics (MNPs) have emerged as a critical environmental pollutant with significant potential implications for the development of liver disease. These MNPs can accumulate in the liver, initiating a series of detrimental biological responses. One of the main mechanisms is the initiation of oxidative stress, which is marked by overproduction of reactive oxygen species harming cellular structures. This oxidative damage is closely linked to hepatic inflammation, where immune responses are triggered, exacerbating tissue injury and disrupting normal liver function. As a result, hepatic metabolism, detoxification, and immune regulation become compromised due to persistent MNPs exposure. Although in vitro and vivo models effectively show direct cellular toxicity, oxidative stress, and metabolic disruption, direct evidence from human studies is mostly confined to tissue detection and cross-sectional correlations. As a result, advanced pathological outcomes like the progression of hepatic fibrosis and the development of cancer are considered mechanistic hypotheses grounded in biological plausibility rather than confirmed human causation.
- 16 October 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (5) , 1253-1254
Rethinking albumin after paracentesis: It’s not just about the volume
Was not provided for this article.
- 16 October 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (5) , 1253-1254
Rethinking albumin after paracentesis: It’s not just about the volume
Was not provided for this article.
- Open Access
- 23 January 2026
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102190
Acute-on-chronic liver failure designation in patients with severe alcohol-associated hepatitis undergoing liver transplantation
- 23 January 2026
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102190
Open AccessAcute-on-chronic liver failure designation in patients with severe alcohol-associated hepatitis undergoing liver transplantation
- Open Access
- 30 September 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (3) , 805-811
Paving a Path Forward After an Unsuccessful GI Fellowship Match
The gastroenterology (GI) fellowship match is among the most competitive subspecialty matches in internal medicine, with approximately 35% of applicants going unmatched annually. For many trainees, not matching can feel like a significant personal and professional setback. However, this moment can also serve as an inflection point for growth and recalibration. Provided in this manuscript is a practical framework to support unmatched re-applicants in navigating the post-match period and strengthening their candidacy for future application cycles. It is essential to acknowledge the emotional impact of an unsuccessful match and allow time for reflection before re-engaging in the process. While there may be a small number of open slots that do not fill and are open for a scramble-type process, this requires rapid action and access to all application materials to be readily sent, at a time when the unmatched applicant is still going through the disappointment of not matching. Re-applicants should seek mentorship and honest feedback to identify gaps in their applications and set clear goals for the upcoming year(s). Strategies to enhance re-applications include engaging in scholarly activity, pursuing structured research or clinical opportunities, strengthening letters of recommendation, and broadening the scope of program applications. Ultimately, while not matching can be a difficult experience, many successful gastroenterologists have faced this challenge and gone on to excel. By reframing the setback as an opportunity to reflect, rethink, and restart, unmatched re-applicants can re-enter the fellowship match process with improved qualifications and a compelling story of perseverance.
- 30 September 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (3) , 805-811
Open AccessPaving a Path Forward After an Unsuccessful GI Fellowship Match
The gastroenterology (GI) fellowship match is among the most competitive subspecialty matches in internal medicine, with approximately 35% of applicants going unmatched annually. For many trainees, not matching can feel like a significant personal and professional setback. However, this moment can also serve as an inflection point for growth and recalibration. Provided in this manuscript is a practical framework to support unmatched re-applicants in navigating the post-match period and strengthening their candidacy for future application cycles. It is essential to acknowledge the emotional impact of an unsuccessful match and allow time for reflection before re-engaging in the process. While there may be a small number of open slots that do not fill and are open for a scramble-type process, this requires rapid action and access to all application materials to be readily sent, at a time when the unmatched applicant is still going through the disappointment of not matching. Re-applicants should seek mentorship and honest feedback to identify gaps in their applications and set clear goals for the upcoming year(s). Strategies to enhance re-applications include engaging in scholarly activity, pursuing structured research or clinical opportunities, strengthening letters of recommendation, and broadening the scope of program applications. Ultimately, while not matching can be a difficult experience, many successful gastroenterologists have faced this challenge and gone on to excel. By reframing the setback as an opportunity to reflect, rethink, and restart, unmatched re-applicants can re-enter the fellowship match process with improved qualifications and a compelling story of perseverance.
- Open Access
- 19 January 2025
- Published by Open Exploration Publishing in Exploration of Medicine
- Vol. 6, 1001275
Gut microbiota-derived metabolites and chronic inflammatory diseases
The gut microbiota, a complex ecosystem of microorganisms, plays an essential role in maintaining immune and metabolic homeostasis. Disruption of this microbial balance, known as dysbiosis, has been increasingly implicated in the pathogenesis of chronic inflammatory conditions, including cardiovascular, gastrointestinal, and autoimmune diseases, as well as metabolic disorders such as diabetes and obesity. A crucial mechanism through which the gut microbiota exerts its effects on host physiology is via the production of bioactive metabolites. These metabolites, including short-chain fatty acids, bile acids, and tryptophan derivatives, are key in modulating immune responses and regulating metabolic functions. Dysbiosis disrupts the production and function of these metabolites, thereby contributing to immune dysregulation, chronic inflammation, and disease progression. This review examines the role of gut microbiota-derived metabolites in chronic inflammatory diseases, with a focus on their immunomodulatory and metabolic effects. A deeper understanding of these mechanisms may open the way for novel therapeutic strategies aimed at restoring immune homeostasis and mitigating the global burden of chronic inflammatory diseases.
- 19 January 2025
- Published by Open Exploration Publishing in Exploration of Medicine
- Vol. 6, 1001275
Open AccessGut microbiota-derived metabolites and chronic inflammatory diseases
The gut microbiota, a complex ecosystem of microorganisms, plays an essential role in maintaining immune and metabolic homeostasis. Disruption of this microbial balance, known as dysbiosis, has been increasingly implicated in the pathogenesis of chronic inflammatory conditions, including cardiovascular, gastrointestinal, and autoimmune diseases, as well as metabolic disorders such as diabetes and obesity. A crucial mechanism through which the gut microbiota exerts its effects on host physiology is via the production of bioactive metabolites. These metabolites, including short-chain fatty acids, bile acids, and tryptophan derivatives, are key in modulating immune responses and regulating metabolic functions. Dysbiosis disrupts the production and function of these metabolites, thereby contributing to immune dysregulation, chronic inflammation, and disease progression. This review examines the role of gut microbiota-derived metabolites in chronic inflammatory diseases, with a focus on their immunomodulatory and metabolic effects. A deeper understanding of these mechanisms may open the way for novel therapeutic strategies aimed at restoring immune homeostasis and mitigating the global burden of chronic inflammatory diseases.
- Open Access
- 21 September 2024
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 48 (10) , 1898-1904
Referral to hepatology is lower in patients with excessive alcohol use who have mental health disorders despite a high fibrosis‐4 index
Background: Alcohol use disorder (AUD) is a multifaceted disease, and integration of AUD treatment between mental health and hepatology is necessary to improve outcomes. We aimed to ascertain whether patients with excessive alcohol use (EAU) and high FIB‐4, which is a non‐invasive method to identify advanced liver disease, are appropriately referred to hepatology and detect which clinical barriers, if any, might pertain.Methods: Records of patients with excessive alcohol use between 2013 and 2023 were extracted from a large public system. Demographics, alcohol‐related hospitalizations, mental health conditions, Charlson comorbidity index (CCI) and referral patterns were evaluated. Comparisons were made between those referred to hepatology versus not.Results: 1131 subjects showed evidence of EAU but on further review, 189 were in alcohol‐remission. The remaining 942 (636 men, age 55.7 ± 14.5 years, 548 white, 363 black, 19 Hispanic) subjects with CCI 2.61 ± 2.23 were further analyzed for FIB‐4 score and referral patterns. 316 patients had active EAU and a high FIB‐4, of whom only 116 (37%) were referred to hepatology. Patients with alcohol‐related mental health concerns and admitted for trauma were less likely to be referred. Logistic regression showed referral was higher with alcohol‐related liver hospitalizations (OR: 9.25, 95% CI: 4.90–17.47, p < 0.001), higher CCI (OR: 6.23, 95% CI: 3.00–12.94, p < 0.0001) and lower with mental health admissions (OR: 0.36, 95% CI: 0.15–0.48, p < 0.001) or mental health diagnoses (OR: 0.36, 95% CI: 0.15–0.82, p = 0.02) and increasing age (OR: 0.95, 95% CI: 0.92–0.97, p < 0.001).Conclusions: In a large public health system, almost 63% of patients with EAU and FIB‐4 >2.67 are not referred to hepatology for evaluation. Patients not referred were more likely to have alcohol‐related mental‐health hospitalizations and mental health diagnoses, while those with liver‐related hospitalizations and comorbidities were more likely to be referred. Greater education of mental health providers and for teams taking care of inpatients admitted with alcohol‐related mental health concerns would better integrate care and improve outcomes for patients with higher risk for advanced liver disease.
- 21 September 2024
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 48 (10) , 1898-1904
Open AccessReferral to hepatology is lower in patients with excessive alcohol use who have mental health disorders despite a high fibrosis‐4 index
Background: Alcohol use disorder (AUD) is a multifaceted disease, and integration of AUD treatment between mental health and hepatology is necessary to improve outcomes. We aimed to ascertain whether patients with excessive alcohol use (EAU) and high FIB‐4, which is a non‐invasive method to identify advanced liver disease, are appropriately referred to hepatology and detect which clinical barriers, if any, might pertain.Methods: Records of patients with excessive alcohol use between 2013 and 2023 were extracted from a large public system. Demographics, alcohol‐related hospitalizations, mental health conditions, Charlson comorbidity index (CCI) and referral patterns were evaluated. Comparisons were made between those referred to hepatology versus not.Results: 1131 subjects showed evidence of EAU but on further review, 189 were in alcohol‐remission. The remaining 942 (636 men, age 55.7 ± 14.5 years, 548 white, 363 black, 19 Hispanic) subjects with CCI 2.61 ± 2.23 were further analyzed for FIB‐4 score and referral patterns. 316 patients had active EAU and a high FIB‐4, of whom only 116 (37%) were referred to hepatology. Patients with alcohol‐related mental health concerns and admitted for trauma were less likely to be referred. Logistic regression showed referral was higher with alcohol‐related liver hospitalizations (OR: 9.25, 95% CI: 4.90–17.47, p < 0.001), higher CCI (OR: 6.23, 95% CI: 3.00–12.94, p < 0.0001) and lower with mental health admissions (OR: 0.36, 95% CI: 0.15–0.48, p < 0.001) or mental health diagnoses (OR: 0.36, 95% CI: 0.15–0.82, p = 0.02) and increasing age (OR: 0.95, 95% CI: 0.92–0.97, p < 0.001).Conclusions: In a large public health system, almost 63% of patients with EAU and FIB‐4 >2.67 are not referred to hepatology for evaluation. Patients not referred were more likely to have alcohol‐related mental‐health hospitalizations and mental health diagnoses, while those with liver‐related hospitalizations and comorbidities were more likely to be referred. Greater education of mental health providers and for teams taking care of inpatients admitted with alcohol‐related mental health concerns would better integrate care and improve outcomes for patients with higher risk for advanced liver disease.
- 23 May 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 30 (12) , 1281-1288
Utility of scores to predict alcohol use after liver transplant: Take them with a grain of salt
Background & Aims: The Sustained Alcohol use post-Liver Transplant (SALT) and the High-Risk Alcohol Relapse (HRAR) scores were developed to predict return to alcohol use after liver transplant (LT) for alcohol associated liver disease (ALD). Methods: A retrospective analysis of deceased donor LT 10/2018 to 4/2022 was performed. All patients (pts) underwent careful pre-LT psychosocial evaluation. Data on alcohol use, substance abuse, prior rehabilitation, and legal issues were collected. Post-LT, all were encouraged to participate in rehabilitation programs and underwent interval phosphatidylethanol (PeTH) testing. Pts with ALD were stratified by < or > 6 month sobriety prior to listing. Those with 6 month sobriety and 85 had Export
- 23 May 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 30 (12) , 1281-1288
Utility of scores to predict alcohol use after liver transplant: Take them with a grain of salt
Background & Aims: The Sustained Alcohol use post-Liver Transplant (SALT) and the High-Risk Alcohol Relapse (HRAR) scores were developed to predict return to alcohol use after liver transplant (LT) for alcohol associated liver disease (ALD). Methods: A retrospective analysis of deceased donor LT 10/2018 to 4/2022 was performed. All patients (pts) underwent careful pre-LT psychosocial evaluation. Data on alcohol use, substance abuse, prior rehabilitation, and legal issues were collected. Post-LT, all were encouraged to participate in rehabilitation programs and underwent interval phosphatidylethanol (PeTH) testing. Pts with ALD were stratified by < or > 6 month sobriety prior to listing. Those with 6 month sobriety and 85 had Export
- Open Access
- 28 February 2024
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 4 (1) , 90-105
Nutritional effects on mucosal integrity and immune function
The intestinal mucosal barrier plays a critical role in maintaining the integrity of the gastrointestinal (GI) tract and protecting the body from harmful toxins and pathogens. Nutrition additionally
- 28 February 2024
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 4 (1) , 90-105
Open AccessNutritional effects on mucosal integrity and immune function
The intestinal mucosal barrier plays a critical role in maintaining the integrity of the gastrointestinal (GI) tract and protecting the body from harmful toxins and pathogens. Nutrition additionally
- Open Access
- 12 October 2023
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 12
Early liver transplantation for severe alcohol-associated hepatitis: A single-center experience
- 12 October 2023
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 12
Open AccessEarly liver transplantation for severe alcohol-associated hepatitis: A single-center experience